Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Zelluna raised NOK 58 million to advance its cancer therapy into Phase I trials.

flag Zelluna ASA completed a private placement and retail offering on November 3, 2025, raising NOK 58 million to advance its ZI-MA4-1 TCR-NK therapy into Phase I trials. flag The company issued 5.5 million shares in the private placement and 315,639 via PrimaryBid, with share lending used for settlement. flag A potential subsequent offering of up to 800,000 shares for existing shareholders is planned, pending approvals and market conditions. flag The total new shares issued could reach 6.615 million, aiming to strengthen capital and support development of its off-the-shelf cancer therapy.

4 Articles